Your browser doesn't support javascript.
loading
CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.
Matsushita, M; Ozawa, K; Suzuki, T; Nakamura, M; Nakano, N; Kanchi, S; Ichikawa, D; Matsuki, E; Sakurai, M; Karigane, D; Kasahara, H; Tsukamoto, N; Shimizu, T; Mori, T; Nakajima, H; Okamoto, S; Kawakami, Y; Hattori, Y.
Afiliação
  • Matsushita M; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Ozawa K; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Suzuki T; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Nakamura M; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Nakano N; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Kanchi S; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Ichikawa D; Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Shiabakoen, Minato-ku, Tokyo, Japan.
  • Matsuki E; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Karigane D; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Kasahara H; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Tsukamoto N; Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Shimizu T; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Nakajima H; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Okamoto S; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan.
  • Kawakami Y; Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Hattori Y; Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan.
Blood Cancer J ; 7(9): e601, 2017 09 01.
Article em En | MEDLINE | ID: mdl-28862699
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Células da Medula Óssea / Leucemia Mielogênica Crônica BCR-ABL Positiva / Regulação Leucêmica da Expressão Gênica / Linfócitos T CD8-Positivos / Proteínas de Neoplasias Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Células da Medula Óssea / Leucemia Mielogênica Crônica BCR-ABL Positiva / Regulação Leucêmica da Expressão Gênica / Linfócitos T CD8-Positivos / Proteínas de Neoplasias Idioma: En Ano de publicação: 2017 Tipo de documento: Article